American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
about
Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancerThe Association of Low-To-Moderate Alcohol Consumption with Breast Cancer Subtypes Defined by Hormone Receptor StatusClinicopathological features of invasive micropapillary carcinoma of the breast.Prognostic and predictive value of low estrogen receptor expression in breast cancerHAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancerMulti-gene fluorescence in situ hybridization to detect cell cycle gene copy number aberrations in young breast cancer patients.Heterogeneity of Diffusion-Weighted Imaging in Tumours and the Surrounding Stroma for Prediction of Ki-67 Proliferation Status in Breast CancerRole of Circulating Tumor Cell (CTC) Monitoring in Evaluating Prognosis of Triple-Negative Breast Cancer Patients in China.Postmastectomy radiotherapy for locally advanced breast cancer receiving neoadjuvant chemotherapy.Understanding the implications of the breast cancer pathology report: a case study.The prediction models for postoperative overall survival and disease-free survival in patients with breast cancerPolarity gene alterations in pure invasive micropapillary carcinomas of the breastPhosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancerCommentary: improving breast cancer testing for patients-the secret sauce is collaboration.Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis.Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information.Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage.Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype.Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused updateSt Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial.A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancerAndrogen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.Optimal systemic therapy for early breast cancer in women: a clinical practice guidelinePrognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.Development and verification of the PAM50-based Prosigna breast cancer gene signature assayAnalysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay.Characteristics and Survival of Breast Cancer Patients with Multiple Synchronous or Metachronous Primary Cancers.Estrogen Receptor Expression Is Associated with DNA Repair Capacity in Breast Cancer.HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features.Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.Hormone Receptor Expression Analyses in Neoplastic and Non-Neoplastic Canine Mammary Tissue by a Bead Based Multiplex Branched DNA Assay: A Gene Expression Study in Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Samples.Association between lifetime exposure to passive smoking and risk of breast cancer subtypes defined by hormone receptor status among non-smoking Caucasian women.Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer.Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective studyPrognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.Update on triple-negative breast cancer: prognosis and management strategiesReproductive history and breast cancer risk.
P2860
Q28084216-56CCD24F-CAB2-444E-9CFC-26B487CD59F3Q28396608-C1B819AD-6C65-4A82-BE4E-5400D165D5F4Q30419281-E5F4E56D-C35C-432A-8DCF-177FE286300CQ33611133-8C48E3B0-D765-47FD-AA9E-C43CDB182994Q33613602-D63C3C2D-D276-4AF2-B891-13C5E7EA798AQ33728390-611FDD27-D6FA-42CA-8E5F-AEFA0130EB64Q33767081-CC72C72B-022F-4CB0-9640-4C02E11BC547Q33858981-5F093191-EF51-489D-9EC9-5D1F772963DAQ33876719-18795778-D302-4076-B1E2-9072DC865B25Q33885989-B5F5A4D8-C4E6-4C15-8FBD-5842AA6C2979Q33891155-78018352-7BDA-4150-AAD8-4BFA8CBE8DD7Q33892823-5BE77952-0A72-434E-AD86-9D2A5CA74CBBQ33913872-667A2047-F23C-49C5-B75F-9A52B683FB9DQ33978931-2DEC9E96-0748-4930-AF9B-C001EFF3DB3FQ34155727-9A482456-BF2C-4B86-ADB5-66D993FCC557Q34169294-C1FB0717-B9B2-4A21-97C2-53C4DBA46CD5Q34203914-0869B141-FEA9-4CFB-8FE1-023FC1D145C4Q34243127-4B87EC35-6676-449C-A7F5-6FC84859C346Q34296534-D58A3D6C-B71E-4A75-A730-624D9F9A97B7Q34351294-17F6C41B-264F-4AF4-AED0-A74A1B9B58B2Q34421634-00C70A81-8781-4144-9E7B-B10248F8DD65Q34463987-3A44A96F-3BAA-4F65-BDBD-D8FD9FFCCF99Q34506546-4EB91BDB-CF2D-4FAB-B12D-3C21EEBBDF4DQ34512957-EB46F2B4-3630-4910-9672-2245ECD4B2C6Q35239634-FFBE12B0-2F42-49E7-8247-AD508683AF9DQ35677713-AA736F8F-8373-41AF-83D6-96BEFE89C967Q35752868-DAD5CC35-F6A1-4254-AA79-B1AC9D39CD71Q35833567-08C0A297-BDFF-4646-A47D-85988A52DABDQ35836711-FB63A533-0B13-4F78-B80D-E62964329024Q35971016-3FDEABD2-4307-43EA-B9AF-47427AE2BD36Q35975638-7D607530-579B-4DDB-844A-79F983EF91A5Q36014239-4C805617-2E0F-4AAF-95FE-C6E6BC448DFCQ36119158-ECB78285-2412-456E-9907-6742D82304FBQ36138577-E651BE70-3755-429A-ADF9-90D1986BCFBCQ36267421-B0C240A7-5D32-48B9-8C95-CBAEA050CDF2Q36271681-488FB562-26E5-4A53-B086-E3C6E9170647Q36288976-D53DCC83-8309-44CD-AAF2-7E8D5E6CA20BQ36299320-C914B2DF-3E63-4C4C-BA3A-45AB347E3C0CQ36311616-E2678156-992C-4C47-A93F-A3E661DD4790Q36342182-117E26A0-7C4D-41B5-8CD1-47EA9F5A9894
P2860
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
American society of clinical o ...... ne receptors in breast cancer.
@en
American society of clinical o ...... ne receptors in breast cancer.
@nl
type
label
American society of clinical o ...... ne receptors in breast cancer.
@en
American society of clinical o ...... ne receptors in breast cancer.
@nl
prefLabel
American society of clinical o ...... ne receptors in breast cancer.
@en
American society of clinical o ...... ne receptors in breast cancer.
@nl
P2093
P2860
P356
P1476
American society of clinical o ...... ne receptors in breast cancer.
@en
P2093
Daniel F Hayes
M Elizabeth H Hammond
Pamela B Mangu
Sarah Temin
P2860
P304
P356
10.1200/JOP.777003
P407
P577
2010-06-23T00:00:00Z